The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Novel testing approaches for the early detection of suspected lymphoproliferative disorders
Anton Langerak, PhD, Erasmus MC, Rotterdam, The Netherlands, discusses novel testing approaches for the early detection of suspected lymphoproliferative disorders. He highlights a novel proteomics approach using plasma protein analysis in pre-diagnostic samples to identify proteins associated with the risk of developing certain lymphoma subtypes. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, I spoke about that and actually continued where I stopped last year. So I was speaking about the new data that we obtained with the immunogenetic and somatic gene analysis, looking into a population cohort, pre-diagnostic samples from individuals that eventually developed CLL and also lymphomas. And so I updated the data that I showed last time now including much more cases especially on different types of lymphomas and also highlighting the occurrence of certain somatic gene events already early on in the pre-diagnostic samples that were taken in those individuals showing already subclonal mutations in, for example, NOTCH1 that finally appeared also to be present in the CLL clone and later on in the Richter transformation stage of the CLLs...
Yes, I spoke about that and actually continued where I stopped last year. So I was speaking about the new data that we obtained with the immunogenetic and somatic gene analysis, looking into a population cohort, pre-diagnostic samples from individuals that eventually developed CLL and also lymphomas. And so I updated the data that I showed last time now including much more cases especially on different types of lymphomas and also highlighting the occurrence of certain somatic gene events already early on in the pre-diagnostic samples that were taken in those individuals showing already subclonal mutations in, for example, NOTCH1 that finally appeared also to be present in the CLL clone and later on in the Richter transformation stage of the CLLs. But my actual contribution of the novel testing approach today was more on proteomics plasma protein analysis using data available in the population cohort that we could analyze for that matter by which we could already identify again in the pre-diagnostic samples proteins that would associate with the risk of developing certain lymphoma subtypes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
